Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors

A compound of Formula B, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof:

• wherein in Formula B:
• Ar and Ar1 are independently selected from a mono- or polycyclic optionally substituted cycloalkyl, mono- or polycyclic optionally substituted heterocycloalkyl, mono- or polycyclic optionally substituted aryl, mono- or polycyclic optionally substituted arylalkyl, mono- or polycyclic optionally substituted heteroaryl, and mono- or polycyclic optionally substituted heteroarylalkyl;
• R1 and R2 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted alkylheteroaryl, wherein R1 and R2 can optionally be joined to form a carbo- or heterocycle;
• L1 and L2 are linkers comprising independently one or more of a bond, —NRa—, —S—, —S(O)—, —S(O)2—, —O—, —CRa2—, —C(O)O—, —OC(O)—, —C(O)S—, —SC(O)—, —C(O)NRa—, —NRaC(O)—, —C(O)NRaSO2—, —SO2NRa C(O)—, —OC(O)O—, —OC(O)S—, —SC(O)O—, —OC(O)NRa—, —NRaC(O)O—, —S(O)tN(Ra)— (where t is 1 or 2), —N(Ra)S(O)t— (where t is 1 or 2), disubstituted alkyl, disubstituted heteroalkyl, disubstituted alkenyl, disubstituted alkynyl, disubstituted cycloalkyl, disubstituted heterocycloalkyl, disubstituted aryl, disubstituted arylalkyl, disubstituted heteroaryl, and disubstituted heteroarylalkyl;
• wherein any optional substituent is independently selected at each occurrence from optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, —ORa, —SRa, —OC(O)—Ra, —SC(O)—Ra, —N(Ra)2, —C(O)Ra, —C(O)ORa, —C(O)SRa, —OC(O)N(Ra)2, —C(O)N(Ra)2, —N(Ra)C(O)ORa, —N(Ra)C(O)Ra, —N(Ra)C(O)N(Ra)2, —N(Ra)C(NRa)N(Ra)2, —N(Ra)S(O)Ra (where t is 1 or 2), —S(O)Ra (where t is 1 or 2), —S(O)tORa (where t is 1 or 2), —S(O)tN(Ra)2 (where t is 1 or 2), and PO3(Ra)2;
• and
• Ra is independently selected at each occurrence from hydrogen, optionally substituted alkyl, optionally substituted fluoroalkyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl.